Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:53 PM
Ignite Modification Date:
2025-12-24 @ 3:53 PM
NCT ID:
NCT01674192
Eligibility Criteria:
Inclusion Criteria:
All subjects had to meet the following inclusion criteria:
* Between the ages of 18 and 75 years, inclusive;
* Males or females. Females were to be of non-childbearing potential.
Normal subjects had to meet the following additional inclusion criteria:
* Demographically comparable to the subjects with renal impairment, within 30% of mean weight and height and 10% of the mean age;
* Physical examination, clinical laboratory results, and 12-lead ECG within normal limits at screening;
* No intake of medication, including over-the-counter medication, during a pre-trial 7-day drug-free washout period;
Subjects with renal impairment had to meet the following additional inclusion criteria:
* Stable severity of renal disease;
* Concomitant medications to treat underlying disease states or medical conditions related to renal insufficiency were allowed;
* Stable dose of medication and/or treatment regimen from 2 months prior to and during the trial;
* Subjects with stable cardiovascular disease could be enrolled, provided that the investigator felt their condition would not interfere with the results of the trial.
Exclusion Criteria:
All subjects who met any of the following criteria were excluded from the trial:
* History of hypersensitivity to prucalopride or inactive ingredients in the prucalopride capsule or to related prokinetic compounds;
* Use of any other investigational drug within 30 days prior to signing the consent or intention to take any investigational drug during the trial;
* History of significant blood loss, or blood plasma donation (500mL) within the last 30 days;
* Pregnancy or breast feeding;
* Gastrointestinal (GI) surgery within 3 months, or history of major GI surgery with potential compromise of drug absorption or metabolism;
Normal subjects who met any of the following criteria were excluded from the trial:
* Any abnormal medical history, physical examination, ECG, or laboratory results;
* Use of medications 7 days prior to and during the trial.
* Subjects with renal impairment who met any of the following criteria were excluded from the trial.
* Any abnormality in medical history, physical examination, ECG, or laboratory results that, in the opinion of the investigator, might affect the safety of the subject;
* History of uric acid stone disease, uricosuria, or gout, or current hyperuricemia;
* Renal transplants, lupus erythematosus, or renal carcinoma.
Study:
NCT01674192
Study Brief:
Protocol Section:
NCT01674192